Global Cancer Biomarkers Market 2015-2019

Global Cancer Biomarkers Market 2015-2019

About Cancer Biomarkers

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report



TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas
• APAC
• EMEA

Key Vendors

• Abbott Laboratories
• Affymetrix
• Illumina
• Qiagen
• Quest Diagnostics
• Roche Diagnostics

Other Prominent Vendors

• Agendia
• Agilent Technologies
• Alere
• Ambry Genetics
• Amgen
• Astellas Pharma US
• Astex Pharmaceuticals
• Atossa Genetics
• Beckman Coulter
• Becton, Dickinson and Company
• Biocurex
• bioMérieux
• Celldex Therapeutics
• Clarient
• diaDexus
• DiagnoCure
• Epigenomics
• EUSA Pharma
• Exact Sciences
• Foundation Medicine
• Fujirebio Diagnostics
• Genomic Health
• Geron
• Immunomedics
• Morphotek
• Myriad Genetics
• Nodality
• Northwest Biotherapeutics
• Ocimum Biosolutions
• Oncothyreon
• OriGene
• Polymedco
• Radient Pharmaceuticals
• Randox Laboratories
• Siemens Healthcare
• US Biomarkers
• Vermillion

Market Driver

• Increased Prevalence of Cancer
• For a full, detailed list, view our report

Market Challenge

• Regulatory and Reimbursement Issues
• For a full, detailed list, view our report

Market Trend

• Growing Popularity of Companion Diagnostics
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Release

TechNavio Announces the Publication of its Research Report – Global Cancer Biomarkers Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Cancer Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Illumina Inc., Qiagen NV, Quest Diagnostics and Roche Diagnostics.

Other Prominent Vendors in the market are: Agendia, Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US, Astex Pharmaceuticals, Atossa Genetics, Beckman Coulter, Becton, Dickinson and Co., Biocurex, bioMérieux, Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma, Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron, Immunomedics, Morphotek, Myriad Genetics, Nodality, Northwest Biotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers and Vermillion.

Commenting on the report, an analyst from TechNavio’s team said: “Growing popularity of companion diagnostics is one of the major trends emerging in this market. Pharmaceutical companies and diagnostic manufacturers are working together to develop such companion diagnostic tests.”

According to the report, the increased prevalence of cancer is one of the key drivers in this market. Globally, the prevalence of cancer is growing at a significant pace. According to researchers, a sedentary lifestyle, poor diet, smoking, and alcohol are among the key external factors contributing to the rise in new cancer cases each year. Some of the internal factors that contribute to the incidence of cancer include inherited mutations, hormonal imbalance, and mutations that occur from metabolism.

Further, the report states that one of the key challenges in the market is the poor regulatory and reimbursement systems. In most countries, regulatory and reimbursement procedures are not ideal to deal with molecular biomarker-based diagnostic tests. Poorly adapted regulatory and reimbursement systems act as a barrier to the inclusion of biomarker-based diagnostic tests in the clinical setting and may further hinder drug development

Companies Mentioned

Abbott Laboratories , Affymetrix , Illumina , Qiagen , Quest Diagnostics, Roche Diagnostics, Agendia , Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US , Astex Pharmaceuticals, Atossa Genetics , Beckman Coulter, Becton, Dickinson and Company,Biocurex, bioMérieux , Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma , Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron , Immunomedics, Morphotek, Myriad Genetics, Nodality, NorthwestBiotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers, Vermillion